Biotest AG
BIESFOTCHealthcare
$32.00
+$0.00(+0.00%)
Market Cap$1.6B
P/E Ratio—
52W High$32
52W Low$30.48
Biotest AG（BIESF）· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · BIESF · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $0.12B | $0.12B | $0.14B | $0.12B | $0.09B |
| Net Receivables | $0.20B | $0.20B | $0.17B | $0.15B | $0.22B |
| Inventory | $0.48B | $0.42B | $0.29B | $0.24B | $0.29B |
| Total Current Assets | $0.81B | $0.76B | $0.62B | $0.52B | $0.56B |
| PP&E Net | $0.57B | $0.48B | $0.55B | $0.55B | $0.55B |
| Goodwill | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Intangible Assets | $0.01B | $0.00B | $0.01B | $0.00B | $0.01B |
| Total Assets | $1.43B | $1.41B | $1.20B | $1.10B | $1.13B |
| Liabilities | |||||
| Short-Term Debt | $0.00B | $0.23B | $0.00B | $0.03B | $0.02B |
| Accounts Payable | $0.09B | $0.08B | $0.05B | $0.04B | $0.04B |
| Total Current Liabilities | $0.16B | $0.39B | $0.13B | $0.11B | $0.11B |
| Long-Term Debt | $0.54B | $0.33B | $0.54B | $0.47B | $0.44B |
| Total Liabilities | $0.90B | $0.91B | $0.83B | $0.72B | $0.69B |
| Stockholders Equity | |||||
| Retained Earnings | $0.27B | $0.24B | $0.11B | $0.12B | $0.18B |
| Total Stockholders Equity | $0.53B | $0.50B | $0.37B | $0.38B | $0.44B |
| Total Liab & Equity(computed) | $1.43B | $1.41B | $1.20B | $1.10B | $1.13B |
| Debt Summary | |||||
| Total Debt | $0.60B | $0.61B | $0.57B | $0.50B | $0.47B |
| Net Debt | $0.49B | $0.51B | $0.46B | $0.39B | $0.40B |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · EUR · B
深入了解Biotest AG
关于Biotest AG（BIESF）资产负债表
Biotest AG总资产$1.43B，现金及短期投资$0.12B，总负债$0.90B，总债务$0.60B，股东权益$0.53B。
常见问题
BIESF · 4 问Biotest AG总债务$0.60B，净债务$0.49B。
BIESF total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10